^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial

Published date:
11/04/2020
Excerpt:
In 10 pts who were refractory to or relapsed after ‘triplet’ therapy, the most frequent mutations at screening were DNMT3A (4), IDH1/2 (4), and N/KRAS (3).
Secondary therapy:
decitabine
DOI:
10.1182/blood-2020-137822